[go: up one dir, main page]

AU2001296000A1 - Nateglinide-containing hydrophilic drug preparations - Google Patents

Nateglinide-containing hydrophilic drug preparations

Info

Publication number
AU2001296000A1
AU2001296000A1 AU2001296000A AU9600001A AU2001296000A1 AU 2001296000 A1 AU2001296000 A1 AU 2001296000A1 AU 2001296000 A AU2001296000 A AU 2001296000A AU 9600001 A AU9600001 A AU 9600001A AU 2001296000 A1 AU2001296000 A1 AU 2001296000A1
Authority
AU
Australia
Prior art keywords
nateglinide
preparation
containing hydrophilic
hydrophilic drug
drug preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296000A
Inventor
Chisato Makino
Nobutaka Ninomiya
Akira Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001296000A1 publication Critical patent/AU2001296000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided a nateglinide-containing hydrophilic pharmaceutical preparation comprising nateglinide B-type crystals as an effective ingredient, the contact angle of the surface of said preparation to water becoming 111 degree or less by incorporating in said preparation at least one hydrophilic substance selected from the groups consisting of hydrophilic polymers, surfactants, sugars, sugar alcohols and salts. This preparation is one having sufficient immediate-release and high dissolution properties, and can be easily prepared. <IMAGE>
AU2001296000A 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations Abandoned AU2001296000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324374 2000-10-24
JP2000-324374 2000-10-24
PCT/JP2001/009292 WO2002040010A1 (en) 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations

Publications (1)

Publication Number Publication Date
AU2001296000A1 true AU2001296000A1 (en) 2002-05-27

Family

ID=18801919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296000A Abandoned AU2001296000A1 (en) 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations

Country Status (19)

Country Link
US (1) US20040029968A1 (en)
EP (1) EP1334721B1 (en)
JP (3) JPWO2002040010A1 (en)
KR (1) KR100829410B1 (en)
CN (1) CN100531730C (en)
AT (1) ATE429217T1 (en)
AU (1) AU2001296000A1 (en)
BR (1) BR0114897A (en)
CA (1) CA2426764C (en)
CY (1) CY1110320T1 (en)
DE (1) DE60138476D1 (en)
DK (1) DK1334721T3 (en)
ES (1) ES2321911T3 (en)
MX (1) MXPA03003686A (en)
PT (1) PT1334721E (en)
RU (1) RU2283104C2 (en)
SI (1) SI1334721T1 (en)
TW (1) TWI289461B (en)
WO (1) WO2002040010A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616561B1 (en) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
ES2307653T3 (en) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. PREPARATIONS CONTAINING NATEGLINIDA.
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
KR100882156B1 (en) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 Nateglinide-containing formulations
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2005094812A1 (en) * 2004-04-01 2005-10-13 Ajinomoto Co., Inc. Nateglinide-containing preparation
WO2009038770A2 (en) * 2007-09-20 2009-03-26 University Of Massachusetts Cvip Detoxified recombinant botulinum neurotoxin
WO2013066278A1 (en) * 2011-11-03 2013-05-10 Mahmut Bilgic A process for production of pharmaceutical formulations comprising nateglinide
WO2013115740A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Synergisctic combination comprising a meglitinide derivative and lipoic acid
CA3176569A1 (en) * 2020-03-27 2021-09-30 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066532B2 (en) * 1983-09-29 1994-01-26 日産化学工業株式会社 Fine waxy powder modified with hydrophilic colloid
JPS6354321A (en) * 1985-03-27 1988-03-08 Ajinomoto Co Inc Blood sugar lowering agent
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69217762T2 (en) * 1991-07-30 1997-10-09 Ajinomoto Kk Crystals of N- (Trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for their preparation
JPH0696517B2 (en) * 1993-03-17 1994-11-30 日産化学工業株式会社 Drug coated with modified waxy fine powder and method for producing the same
JP2994956B2 (en) * 1994-05-31 1999-12-27 信越化学工業株式会社 Low-substituted hydroxypropylcellulose, composition thereof and tablet thereof
KR100343062B1 (en) * 1996-11-15 2002-07-02 에가시라 구니오 Tabletted preparation
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3591801B2 (en) * 1997-06-19 2004-11-24 田辺製薬株式会社 Manufacturing method of oral disintegrating preparation
JP2000178183A (en) * 1998-12-17 2000-06-27 Lion Corp Solid preparation and method for producing the same
JP2000290171A (en) * 1999-04-06 2000-10-17 Eisai Co Ltd Fast collapsable tablet and its production
EP1616561B1 (en) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
KR100873585B1 (en) * 2000-03-17 2008-12-11 아지노모토 가부시키가이샤 Drugs for diabetic complications
PT1334963E (en) * 2000-10-18 2007-09-20 Ajinomoto Kk Process for producing nateglinide crystal
RU2287520C2 (en) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Acylphenylalanine preparation process
ES2307653T3 (en) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. PREPARATIONS CONTAINING NATEGLINIDA.
CA2426745C (en) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Methods for producing nateglinide b-type crystals
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
JP2013064018A (en) 2013-04-11
KR20030042028A (en) 2003-05-27
BR0114897A (en) 2003-08-12
KR100829410B1 (en) 2008-05-15
TWI289461B (en) 2007-11-11
DK1334721T3 (en) 2009-07-06
MXPA03003686A (en) 2004-01-26
JPWO2002040010A1 (en) 2004-06-03
CN1482904A (en) 2004-03-17
CA2426764A1 (en) 2003-04-23
EP1334721A4 (en) 2005-11-02
CN100531730C (en) 2009-08-26
JP2010095551A (en) 2010-04-30
US20040029968A1 (en) 2004-02-12
SI1334721T1 (en) 2009-08-31
RU2283104C2 (en) 2006-09-10
CA2426764C (en) 2010-04-20
PT1334721E (en) 2009-06-01
ATE429217T1 (en) 2009-05-15
EP1334721A1 (en) 2003-08-13
DE60138476D1 (en) 2009-06-04
JP5673972B2 (en) 2015-02-18
ES2321911T3 (en) 2009-06-15
EP1334721B1 (en) 2009-04-22
CY1110320T1 (en) 2015-01-14
WO2002040010A1 (en) 2002-05-23
JP5278708B2 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
CY1110320T1 (en) NATEGLINIDE CONTENTS
ES2402544T3 (en) Quickly soluble film preparation
KR100890180B1 (en) Oral and Oral Dosing Agents
US5102666A (en) Calcium polycarbophil controlled release composition and method
CA2321267A1 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
CA2413334A1 (en) Stabilized interleukin 2
EP1243269A3 (en) Opioid formulations having extended controlled release
AU1301199A (en) Drug delivery systems utilizing liquid crystal structures
CA2386690A1 (en) Pharmaceutical tramadol salts
BR9609663A (en) Formulations for controlled release of poorly soluble drugs
CA2237306A1 (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
CA2015536A1 (en) Pharmaceutical formulation
ES2403069T3 (en) Oral controlled release composition containing levetiracetam
CA2419993A1 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
CA2215327A1 (en) Formulations for lipophilic compounds
EP0350701A3 (en) Pharmaceutical cmpositions for oral administration having analgesic and anti-inflammatory activity, possessing excellent palatability and being free of irritating effects on mucous membranes
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
RU2003111949A (en) HYDROPHILIC PHARMACEUTICAL PRODUCT CONTAINING NATEGLINIDE
DE69119217T2 (en) COMPOSITIONS FOR CONTROLLED RELEASE
US20030064101A1 (en) Floating osmotic device for controlled release drug delivery
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2340898A1 (en) Compositions and methods for treating intracellular infections
AR003131A1 (en) PREPARED FOR CONTROLLED RELEASE IN MULTIPLE PARTICLES BASED ON AN ACTIVE ALKALINIZING POTASSIC SALT SUITABLE FOR PRODUCING AN ORAL PHARMACEUTICAL FORM AND TABLETS OBTAINED.
EP0916621A3 (en) Water having a superior ability to disperse oil and fats